Design Therapeutics director Deepa Prasad to resign

Design Therapeutics, Inc. reported a governance change, stating that board member Deepa Prasad has decided to resign from the Company’s Board of Directors.

Rhea-AI Filing Summary

Design Therapeutics, Inc. reported a governance change, stating that board member Deepa Prasad has decided to resign from the Company’s Board of Directors. Her resignation is effective February 1, 2026 and is attributed to conflict-avoidance policies tied to her newly appointed role with a major bank.

The filing does not describe any disagreement with the Company, instead framing the departure as a compliance requirement related to her new external position. Design Therapeutics remains listed on the Nasdaq Global Select Market under the ticker DSGN, with Pratik Shah continuing as President, Chief Executive Officer and Chairperson.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

What board change did Design Therapeutics (DSGN) disclose in this 8-K?

Design Therapeutics disclosed that director Deepa Prasad decided to resign from its Board of Directors, effective February 1, 2026. The company attributes her resignation to required conflict-avoidance policies tied to her newly appointed role with a major bank, not to a dispute.

When is Deepa Prasad’s resignation from Design Therapeutics’ board effective?

Her resignation from the Design Therapeutics Board of Directors becomes effective on February 1, 2026. The 8-K states that she notified the company of her decision on January 29, 2026, providing a short transition period between notice and effectiveness of the change.

Why is Design Therapeutics director Deepa Prasad resigning from the board?

The filing explains that Deepa Prasad is resigning due to required conflict-avoidance policies connected to her newly appointed role with a major bank. This frames the departure as a compliance and conflict-management issue rather than a disagreement with Design Therapeutics’ strategy or operations.

Does Design Therapeutics link Deepa Prasad’s resignation to any disagreement with the company?

The company does not indicate any disagreement with Design Therapeutics as the reason for her resignation. Instead, the 8-K attributes her decision solely to conflict-avoidance policies associated with her new role at a major bank, suggesting a governance and compliance-driven change.

Who signed the Design Therapeutics 8-K announcing the board resignation?

The 8-K was signed on behalf of Design Therapeutics by Pratik Shah, Ph.D. He is identified in the document as the company’s President, Chief Executive Officer and Chairperson, underscoring his continuing leadership roles following the announced board change.

On which exchange is Design Therapeutics (DSGN) listed and what security is registered?

Design Therapeutics lists its common stock with a par value of $0.0001 per share on the Nasdaq Global Select Market. The trading symbol disclosed in the filing is DSGN, confirming the exchange and security class for investors reviewing this governance update.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 04:05 PM Learn about SEC filing dates

false 0001807120 0001807120 2026-01-29 2026-01-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 29, 2026

Design Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40288		82-3929248
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

6005 Hidden Valley Road, Suite 110 Carlsbad, California		92011
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 293-4900

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		DSGN		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

On January 29, 2026, Deepa Prasad notified Design Therapeutics, Inc. (the “Company”) of her decision to resign from the Company’s Board of Directors, effective February 1, 2026, due to required conflict-avoidance policies associated with her newly appointed role with a major bank.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

				DESIGN THERAPEUTICS, INC.
Date: January 30, 2026				By:		/s/ Pratik Shah
						Pratik Shah, Ph.D.
						President, Chief Executive Officer and Chairperson